CORE in the News

Mice that received antibodies from Long COVID patients showed symptoms including pain and dizziness, a Yale-led study has found.

The Yale School of Public Health had a strong showing at this year’s Aspen Ideas: Health Festival, a three-day gathering of global thought leaders and innovators who engaged in captivating discussions about current health challenges and shared bold ideas for improving health in the future.

The Journal of the American College of Cardiology (JACC), one of the leading cardiovascular journals worldwide, recently named several Yale faculty members to its editorial board.

A landmark Supreme Court decision that reins in federal agencies’ authority is expected to hold dramatic consequences for the nation’s health care system, calling into question government rules on anything from consumer protections for patients to drug safety to nursing home care. YSPH Professor Dr. Joseph Ross provides insight.

A landmark Supreme Court decision that reins in federal agencies’ authority is expected to hold dramatic consequences for the nation’s healthcare system, calling into question government rules on anything from consumer protections for patients to drug safety to nursing home care.

Many patients receive a standardized lipid panel as part of a yearly physical that includes testing of their “good” cholesterol (high-density lipoprotein) and “bad” cholesterol (low-density lipoprotein). However, most people are unfamiliar with another type of cholesterol, lipoprotein(a) or Lp(a). This type of lipoprotein is not included in the standard lipid panel but is an independent risk factor for cardiovascular disease. In the following Q&A, Yale clinicians and researchers share background about Lp(a), guidance for caring for patients with elevated levels, and new approaches to improve testing.

Drugs for serious or life-threatening diseases can receive expedited U.S. Food and Drug Administration (FDA) review, allowing patients to receive faster access to promising new treatments. Under the expedited review pathway of accelerated approval, drugs can be FDA-approved based on surrogate markers or proxy measures such as changes in imaging or lab tests that are “reasonably likely” to predict whether patients improve in how they feel, function, or survive.

YSPH Dean Megan L. Ranney, MD, and Ijeoma Opara, associate professor of social and behavioral sciences, are attending the Aspen Ideas: Health conference June 20-23 in Aspen, Colorado. Ranney will participate in three panel discussions; Opara is an Aspen Ideas: Health Fellow.